As we and others have found IgG3 to have strong effector functions through both Fcγ receptor [11,12] and complement [11,13,25], we now tested if H435-IgG3 has superior effector functions as therapeutic antibody (TA99) in the B16 melanoma model. This evidence concerns the gene IGHG3 and melanoma.